Welcome to our dedicated page for Sharps Technology SEC filings (Ticker: STSSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sharps Technology Inc. (STSSW) SEC filings page aggregates regulatory documents for Sharps Technology, Inc., a Nevada corporation whose common stock trades on Nasdaq under the symbol STSS. These filings provide detailed insight into the company’s medical device and pharmaceutical packaging activities, its Solana-focused digital asset treasury strategy, and the capital markets transactions that support both areas. Investors analyzing STSSW, which represents warrants linked to Sharps Technology’s common stock, can use these filings to understand the underlying corporate structure and key contractual arrangements.
Form 8-K current reports disclosed by the company describe material definitive agreements, including securities purchase agreements for private placements of common stock, pre-funded warrants, and stapled warrants. These documents explain how Sharps Technology raised funds to acquire SOL, the native asset of the Solana blockchain, and to establish Solana treasury operations, as well as the terms of registration rights agreements, warrant amendments, and at-the-market offering arrangements. Additional 8-K disclosures outline strategic advisor and consulting agreements connected to the company’s crypto technology and treasury activities.
Definitive proxy statements on Schedule 14A (DEF 14A) offer further context on governance and shareholder approvals. These filings cover items such as the election of directors, approval of equity incentive plans, increases in authorized common stock, and special meeting proposals to approve share issuances upon exercise of pre-funded and stapled warrants, including those associated with cryptocurrency-related financings and strategic advisor warrants. Together, these materials document how Sharps Technology structures and seeks stockholder approval for key elements of its financing and treasury strategy.
On this page, users can access these SEC filings as they become available through EDGAR, and can use AI-powered tools to summarize complex documents such as proxy statements and current reports. This helps readers quickly identify provisions related to warrant terms, share issuance approvals, treasury strategy disclosures, and advisory and consulting arrangements that are relevant when evaluating Sharps Technology and securities tied to it, such as STSSW.
Paul K. Danner, a director of Sharps Technology Inc. (STSS), was granted options to purchase 400,000 shares at an exercise price of $6.41 per share. The grant was reported with a transaction date of 08/22/2025 and the option is scheduled to become 100% vested and exercisable on May 22, 2026. Following the reported transaction, Mr. Danner beneficially owns 400,000 shares subject to the option on a direct basis. The grant was made pursuant to the company's 2025 Equity Incentive Plan.
Brenda Baird Simpson, a director of Sharps Technology Inc. (ticker: STSSW), was granted a non‑derivative option to purchase 20,000 shares on 08/22/2025 at an exercise price of $6.41 per share. The option was granted under the company’s 2025 Equity Incentive Plan and "will become 100% vested as of the date of issuance," per the filing. Following the grant, Ms. Simpson directly beneficially owns 20,000 shares/options reported on this Form 4.
Sharps Technology, Inc. entered into cash and cryptocurrency private placement agreements to sell common stock, pre-funded warrants and stapled warrants, targeting estimated aggregate gross proceeds of about $400 million before fees to implement a Solana-focused treasury strategy. Cash investors will pay in U.S. dollars or stablecoins, while cryptocurrency investors will pay in SOL tokens, with related warrants generally exercisable at $0.0001 for pre-funded shares and $9.75 for stapled warrants, subject in part to stockholder approval.
The company plans to use proceeds to buy SOL via open-market purchases, build Solana treasury operations, and for general corporate purposes, held in a separate account. Authorized common shares were increased from 1,666,667 to 500,000,000, significantly expanding potential issuance capacity. Existing Series A warrants for 347,774 shares had their exercise price cut from $87.60 to $6.50.
Leadership changed as CEO and director Robert M. Hayes resigned, receiving a $1.2 million lump-sum payment, extended benefits and fully vested options for 100,000 shares. Paul K. Danner became Executive Chairman and Principal Executive Officer with a $600,000 annual salary, and Yuwen (Alice) Zhang was appointed Chief Investment Officer and director, also with a $600,000 base salary. The company signed a settlement term sheet over prior litigation that could materially affect its financial position if the offering is not completed, and a non-binding LOI under which the Solana Foundation may sell $50 million of SOL to the company at a 15% discount following a public offering.
Sharps Technology, Inc. is registering 2,000,000 common shares on Form S-8 for issuance under its 2025 Equity Incentive Plan.
The plan is designed to provide compensation, enticement, and incentive awards, allowing the company to grant equity-based awards to eligible participants. The filing also outlines Nevada law and corporate provisions that allow the company to indemnify its directors, officers, employees, and agents in certain circumstances, and notes that Sharps maintains directors’ and officers’ liability insurance. Standard undertakings confirm that future SEC reports will update this registration by reference.
Altium Capital Management LLC, Altium Healthcare Long Short Onshore Fund LP and Altium Healthcare Long Short GP LLC jointly report beneficial ownership of 35,659 shares of Sharps Technology Inc. common stock issuable upon conversion of Series A warrants, representing 3.48% of the class based on 1,023,214 shares outstanding.
The filing notes the Series A warrants are subject to a 9.99% Warrant Blocker that prevents exercise to the extent it would raise ownership above that threshold. The cover-page figures include the full number of shares issuable on conversion and do not give effect to the Warrant Blocker, so the actual number of shares the reporting persons could beneficially own after giving effect to the blocker is less than the reported amount. Reported sole voting and dispositive power are 0, with 35,659 shared voting and dispositive power.
Sharps Technology, Inc. reported its first product revenue in the quarter of $222,722 and recorded a gross loss of $1,032,027 primarily driven by cost of goods and an inventory reserve. Total assets rose to $17,085,197 and cash increased to $8,322,192, reflecting net proceeds of approximately $18.2 million from a January 2025 equity offering and partial repayment of debt.
For the six months ended June 30, 2025 the company reported net income of $5,488,141, largely attributable to a noncash fair‑value gain on warrants of $11,087,700; warrant liabilities were $1,312,848 at period end. Management discloses substantial doubt about going concern and expects to seek additional financing. The filing also discloses legal claims including a lawsuit alleging up to $1.762 million and an arbitration claim of $500,000, plus equipment purchase commitments of approximately $4.7 million.